RxDoctor Payments Data

Dorota Whitmer, MD

Endocrinology, Diabetes & Metabolism · Lakewood, OHNPI 1528232998

Payments from drug & device makers

$1,993in general payments, 2019–2025

Across 70 payments — averaging $28.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$461
  • Medtronic$363
  • Abbott$316
  • Xeris Pharmaceuticals, Inc.$313
  • Insulet Corporation$166
  • Ascendis Pharma Endocrinology Inc$107
  • plus $267 from 7 others

What the payments were for

  • Food & beverage$1,993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,993 in reported general payments places this provider in the 55th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$30,467
Medicare patients
211
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide127$159,415
OzempicSemaglutide93$116,318
MounjaroTirzepatide90$112,404
JardianceEmpagliflozin68$79,071
JanuviaSitagliptin Phosphate50$55,230
FiaspInsulin Aspart (Niacinamide)12$34,333
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/734$29,574
TradjentaLinagliptin20$24,403
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$23,939
FarxigaDapagliflozin Propanediol31$23,206
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$16,640
Lantus SolostarInsulin Glargine,hum.Rec.Anlog116$14,701
Humalog Kwikpen U-100Insulin Lispro32$13,321
Gvoke Hypopen 2-PackGlucagon21$12,962
Insulin Lispro Kwikpen U-100Insulin Lispro49$11,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humalog$38$284,819241 claims
Novo NordiskOzempic, Fiasp, Novolog$72$160,036125 claims
AstraZenecaFarxiga$13$23,20631 claims
Sanofi-aventis U.S. LLCLantus$71$4,50927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Lakewood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →